https://doi.org/10.31288/oftalmolzh201756065

Biological therapy in treatment of uveitis. Contemporary trends

A.V. Zborovskaia, Dr Sc (Med), A.E. Dorokhova, Cand Sc (Med)

Filatov Institute of Eye Diseases and Tissue Therapy of NAMS of Ukraine

Odessa (Ukraine)

E-mail: filatov.uveitis@gmail.com

Uveitis is a cause of blindness in about 10% of cases. According to many studies, TNF-? plays an important role in the development of uveitis. Anti-TNF-? are widely used in rheumatology and recently in ophthalmology. We carried out the analysis of literature on the use of anti-TNF-?. Large studies have been carried out and good results of anti-TNF-? usage in uveitis associated with JIA, Behcet's disease, ankylosing spondylarthropathies, sarcoidosis have been obtained. The profile of side effects and safety anti-TNF-? is quite acceptable for use in clinical practice. It is highly important that anti-TNF-? has a corticosteroid preserving effect which reduces side-effects associated with treatment, at this time has high efficacy of therapy.

Key-words: uveitis, anti TNF, adalimumab  

References

1.Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group: recommendations for the evaluation of intraocular inflammatory disease. Am. J. Ophthalmol. 1987;103:234–5. 
   Crossref   Pubmed

2.Chang JH, Wakefield D. Uveitis: a global perspective. Ocul. Immunol. Inflamm. 2002;10:263–79.
   Crossref   Pubmed

3.Smit RL, Baarsma GS. Epidemiology of uveitis. Curr Opin Ophthalmol. 1995;6:57– 61.
   Crossref   Pubmed

4.Rothova A, Buitenhuis HJ, Meenken C et al. Uveitis and systemic disease. Br J Ophthalmol. 1992;76:137– 41.
   Crossref   Pubmed

5.Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005.;140(3):509-16.
   Crossref   Pubmed

6.Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–16.
   Crossref   Pubmed

7.Mahendradas P, Khanna A, Kawali A et al. Quantification of inflammation in inflammatory eye diseases.Internet journal of rheumatology and and clinical immunology. 2014;2:1. 
   Crossref

8.Lightman S, Towler H. Immunopathology and altered immunity in posterior uveitis in man: a review. Curr Eye Res. 1992;11:11–15.
   Crossref   Pubmed

9.Becker MD, Adamus G, Davey MP, Rosenbaum JT. The role of T cells in autoimmune uveitis. Ocul Immunol Inflamm. 2000;8:93–100.

10.Murray PI. Anti-TNF-alpha therapy for uveitis: Beh?et and beyond. Sivaraj Eye (Lond). – 2005;19:831– 8.

11.Tracey D, Klareskog L, Sasso EH et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–79.

12.Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002; 2(5):364–71.

13.Neri P, Zucchi M, Allegri P. Adalimumab (Humira): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int Ophthalmol. 2011;31(2):165–73.

14.P?rez-Guijo V, Santos-Lacomba M, S?nchez-Hern?ndez M. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27.Curr Med Res Opin. 2004;20:155–7.

15.Santos Lacomba M, Marcos Mart?n C, Gallardo Galera JM et al. Aqueous humor and serum tumor necrosis factoralpha in clinical uveitis. Ophthalmic Res. 2001;33:251–5.

16.Dick A D. Immune mechanisms of uveitis: insights into disease pathogenesis and treatment. Int. Ophthalmol. Clin. 2000;40(2):1–18.

17.Diaz-Llopis M, Salom D, Garcia-de-Vicuna C. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012; 119(8):1575–81.

18.Makamura S, Yamakawa T, Sugita  M et al. The role of tumor–necrosis factor alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalm Vis Sei. 1994;35:3884–89.

19.Sartani G. Anti–tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 1996;37:2211–8.

20.Mo JS, Matsukawa A, Ohkawara S et al. Involvement of TNF alpha, IL-1 beta and IL-1 receptor antagonist in LPS-induced rabbit uveitis. Exp Eye Res. 1998;66(5):547–57.

21.Dunn JP. Uveitis. Prim Care. 2015;42(3):305–23.

22.Taylor SR, Isa H, Joshi L et al. New developments in corticosteroid therapy for uveitis. Ophthalmologica. 2010;224:46 –53.

23.Castiblanco С, Foster C. Stephen. Review of Systemic Immunosuppression for Autoimmune Uveitis. Ophthalmol. Ther. 2014;3(1-2):17–36.

24.Balevic SJ, Rabinovich CE. Profile of adalimumab and its potential in the treatment of uveitis. Drug Des Devel Ther. 2016;10: 2997–3003.

25.Rabinovich CE. Use of tumor necrosis factor inhibitors in uveitis. Curr Opin Rheumatol. 2007; 19(5):482–6.

26.Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18:481– 6.

27.Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl. 2005;74:13–8.

28.Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum. 2005;34(5 Suppl 1):12–8.

29.Instructions for medical use of Humira®. The Order of MOH of Ukraine No247 from 09.03.2017 (as a single-use pen of adalimumab, 40 mg/0.8 ml). Authorization No UA/13612/01/01.

30.Sarah L, Clarke N, Ethan S. Juvenile idiopathic arthritis-associated uveitis. Pediatric Rheumatology. 2016;14:27

31.Simonini G, Druce K, Cimaz R et al. Current evidence of anti-tumor necrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken). 2014; 66(7):1073–84.

32.Ramanan AV, Dick AD, Benton D et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).Trials. 2014;15:14.

33.Ramanan AV, Dick AD, McKay A. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis [abstract]. Arthritis Rheumatol. 2015;67 (Suppl 10).

34.Simonini G, Taddio A, Cattalini M et al. Prevention of flare recurrences in childhood refractory chronic uveitis: an openlabel comparative study of adalimumab versus infliximab. Arthitis Care Res (Hoboken). 2011;63:612–8.

35.Zannin ME, Birolo C, Gerloni VM et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow up data from the Italian Registry. J Rheumatol. 2013;40(1):74–9.

36.Levy-Clarke G, Jabs DA, Read RW et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–96.

37.Rajesh K, Kataria DO, Lawrence H et al. Spondyloarthropathies. Am Fam Physician. 2004;69(12):2853-60. 

38.Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008;67(7):955–9.

39.Rudwaleit M, Rodevand E, Holck P et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68(5):696–701. 

40.Vallet H, Riviere S, Sanna A et al. Efficacy of anti-TNF alpha in severe and/or refractory Behcet’s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67–74. 

41.Takase K, Ohno S, Ideguchi H et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Beh?et disease-related uveitis. Rheumatol Int. 2011;31:243–5.

42.Erckens RJ, Mostard RL, Wijnen PA et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012; 250(5):713–20.

43.Hamam RN, Barikian AW, Antonios RS et al. Intravitreal adalimumab in active noninfectious uveitis: a pilot study. Ocul Immunol Inflamm. 2016;24(3):319–26. 

44.Callejas-Rubio JL, S?nchez-Cano D, Garc?a Serrano JL et al. Adalimumab therapy for refractory uveitis: a pilot study [letter]. J. Ocul. Pharmacol. Ther. 2008;24:613–4. 

45.Suhler EB, Lowder CY, Goldstein DA. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97(4):481–6.

46.Durrani K, Kempen JH. Adalimumab for ocular inflammation. Ying Ocul Immunol Inflamm. 2016:1–8. 

47.Diak P, Siegel J, La Grenade L, Choi L et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010;62(8):2517–24.

48.Mariette X, Matucci-Cerinic M, Pavelka K. et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70 (11):1895–904.

49.Park HJ, Ranganathan P. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted? Discov Med. 2012;13(70):229–34.

50.Schmeling H, Minden K, Foeldvari I et al. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol. 2014; 66(9):2580–9.